Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

T-1301 is a novel small-molecule inhibitor of multiple kinases being developed as an oral drug for the treatment of advanced solid tumors. The nonclinical study results demonstrate the nonclinical efficacy and safety of T-1301 and support the design of this Phase 1, first-in-human (FIH) clinical trial in subjects with advanced cancer. This study is an open-label, multi-center, Phase I dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of T-1301 capsules in subjects with advanced solid tumors (including lymphoma), and to identify the maximum tolerated dose (MTD) a

Trial Details

NCT ID
NCT05156203
Phase
PHASE1
Sponsor
Taivex Therapeutics Corporation
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • T-1301 Capsules
Locations (sample)
  • Kaohsiung City, Taiwan|22.61626,120.31333
  • Taipei, Taiwan|25.05306,121.52639
  • Taoyuan City, Taiwan|24.99368,121.29696

Key Eligibility Criteria

  • Having signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study.
  • Subjects with histologically and cytologically confirmed advanced solid tumors (including lymphoma) that are refractory to standard treatments, or …
  • Solid tumors that are measurable or evaluable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions that have been previou…
  • Have a life expectancy of ≥ 3 months in the Investigator's opinion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →